Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06697197 · ClinicalTrials.gov registry record · Phase 1
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 413
- Enrollment target
- 20
- Study locations
NCT06697197 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 413 participants, above the 196-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (111% higher). The trial reports 20 study locations across 18 states.
The verdict
NCT06697197, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 413 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG BMS-986482
- DRUG Nivolumab and rHuPH20
- DRUG Nivolumab/relatlimab/rHuPH20
Study Locations (20)
California
- University of California, Irvine (UCI) Health - UC Irvine Medical Center - Irvine
- The Angeles Clinic and Research Institute - West Los Angeles Office - Los Angeles
Other
- Erasmus Medisch Centrum - Rotterdam
- Hospital Universitario HM Sanchinarro - Madrid
Colorado
- Local Institution - 0008 - Aurora
New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center - Hackensack
New York
- Northwell Health/ RJ Zuckerberg Cancer Center - Lake Success
North Carolina
- Levine Cancer Institute - Charlotte
Washington
- Fred Hutchinson Cancer Center - Seattle
Oost-Vlaanderen
- UZ Gent - Ghent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 413 participants |
| Start Date | 2025-02-17 |
| Est. Completion | 2029-01-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06697197
The ClinicalTrials.gov registry entry for NCT06697197 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 413 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 196-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (111% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 4 interventions - of which Bevacizumab is the first listed.
NCT06697197 reports 20 study locations spanning 18 distinct geographic areas - top geographies include California, Other, Colorado.
Frequently Asked Questions
What is clinical trial NCT06697197 about?
NCT06697197 is a clinical study titled "A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors". The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.
What is the current status of trial NCT06697197?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 413 participants. The study started on 2025-02-17. Estimated completion is 2029-01-05.
What conditions does trial NCT06697197 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT06697197?
The interventions under investigation include: Bevacizumab (DRUG), BMS-986482 (DRUG), Nivolumab and rHuPH20 (DRUG), Nivolumab/relatlimab/rHuPH20 (DRUG).
Who is sponsoring clinical trial NCT06697197?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06697197 being conducted?
This trial has 20 study locations across California, Colorado, New Jersey, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.